These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220 [TBL] [Abstract][Full Text] [Related]
44. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature]. Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961 [TBL] [Abstract][Full Text] [Related]
45. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort. Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690 [TBL] [Abstract][Full Text] [Related]
46. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood. Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726 [TBL] [Abstract][Full Text] [Related]
47. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. Thornburg CD; Calatroni A; Panepinto JA J Pediatr Hematol Oncol; 2011 May; 33(4):251-4. PubMed ID: 21516020 [TBL] [Abstract][Full Text] [Related]
48. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171 [TBL] [Abstract][Full Text] [Related]
49. Hydroxyurea in children: present and future. Vichinsky EP Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198 [TBL] [Abstract][Full Text] [Related]
50. Do difficulties in swallowing medication impede the use of hydroxyurea in children? Bekele E; Thornburg CD; Brandow AM; Sharma M; Smaldone AM; Jin Z; Green NS Pediatr Blood Cancer; 2014 Sep; 61(9):1536-9. PubMed ID: 24753149 [TBL] [Abstract][Full Text] [Related]
51. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Ferster A; Tahriri P; Vermylen C; Sturbois G; Corazza F; Fondu P; Devalck C; Dresse MF; Feremans W; Hunninck K; Toppet M; Philippet P; Van Geet C; Sariban E Blood; 2001 Jun; 97(11):3628-32. PubMed ID: 11369660 [TBL] [Abstract][Full Text] [Related]
52. Hydroxyurea and growth in young children with sickle cell disease. Rana S; Houston PE; Wang WC; Iyer RV; Goldsmith J; Casella JF; Reed CK; Rogers ZR; Waclawiw MA; Thompson B; Pediatrics; 2014 Sep; 134(3):465-72. PubMed ID: 25157002 [TBL] [Abstract][Full Text] [Related]
53. Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not. Nwenyi E; Leafman J; Mathieson K; Ezeobah N Int J Health Care Qual Assur; 2014; 27(6):468-81. PubMed ID: 25115050 [TBL] [Abstract][Full Text] [Related]
54. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898 [TBL] [Abstract][Full Text] [Related]
55. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017. Su ZT; Segal JB; Lanzkron S; Ogunsile FJ Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369 [TBL] [Abstract][Full Text] [Related]
56. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Green NS; Barral S Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885 [TBL] [Abstract][Full Text] [Related]
57. Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Hankins JS; Penkert RR; Lavoie P; Tang L; Sun Y; Hurwitz JL Exp Biol Med (Maywood); 2016 Apr; 241(7):749-54. PubMed ID: 26940953 [TBL] [Abstract][Full Text] [Related]
58. [Sickle cell anemia in children: value of hydroxyurea in severe forms]. Oury AP; Hoyoux C; Dresse MF; Chantraine JM Arch Pediatr; 1997 Sep; 4(9):839-44. PubMed ID: 9345564 [TBL] [Abstract][Full Text] [Related]
59. Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol. Gwer SO; Onyango KO JBI Database System Rev Implement Rep; 2018 May; 16(5):1135-1140. PubMed ID: 29762306 [TBL] [Abstract][Full Text] [Related]